drugset / Trial / NCT00927550

Lithium and Standard Therapy in Resistant Depression

NCT00927550 ↗

Phase 4 Unknown 230 enrolled University of Verona
RandomizedParallel-groupOpen-labelTreatment

Summary

The principal clinical question is whether lithium is effective in reducing the risk of suicidal behaviour in subjects with treatment-resistant depression and suicide risk. Additionally aims of the study are: (a) to assess whether lithium is effective in improving depressive symptomatology in subjects with treatment-resistant depression and suicide risk; (b) to assess the tolerability profile of lithium.

Timeline

Start
2009-06
Primary completion
2012-12
Completion
2012-12

Outcome

Missed primary endpoint

paper The survival probability did not differ between the two treatment arms (Chi2 = 0.17, p =0.676). PMID 25326163 ↗

paper Consequently, the finding that lithium, in addition to usual care, did not exert a positive effect in terms of reduction of DSH after 12 months of follow-up PMID 25326163 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Unknown 150 mg Oral
Subject Lithium Unknown 300 mg Oral

Indications